Search

Your search keyword '"Plieskatt, Jordan L."' showing total 14 results
Start Over Author "Plieskatt, Jordan L." Search Limiters Full Text
14 results on '"Plieskatt, Jordan L."'

1. A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabe adults

Author

Tiono, Alfred B., Plieskatt, Jordan L., Ouedraogo, Alphonse, Soulama, Ben Idriss, Miura, Kazutoyo, Bougouma, Edith C., Naghizadeh, Mohammad, Barry, Aissata, Yaro, Jean Baptist B., Ezinmegnon, Sem, Henry, Noelie, Ofori, Ebenezer Addo, Adu, Bright, Singh, Susheel K., Konkobo, Augustin, Bengtsson, Karin Lovgren, Diarra, Amidou, Carnrot, Cecilia, Reimer, Jenny M., Ouedraogo, Amidou, Tienta, Moussa, Long, Carole A., Ouedraogo, Issa N., Sagara, Issaka, Sirima, Sodiomon B., and Theisen, Michael

Subjects
Control, Testing, Identification and classification, Prevention, Risk factors, Malaria vaccines -- Testing, Plasmodium falciparum -- Identification and classification -- Control, Malaria -- Risk factors -- Prevention, Malaria vaccine -- Testing
Abstract

Introduction Plasmodium falciparum malaria is transmitted by mosquitoes of the genus Anopheles. During a blood meal from an infected person, the female mosquito ingests sexual-stage parasites, which fertilize in the [...], BACKGROUND. Malaria transmission-blocking vaccines aim to interrupt the transmission of malaria from one person to another. METHODS. The candidates R0.6C and ProC6C share the 6C domain of the Plasmodium falciparum sexual-stage antigen Pfs48/45. R0.6C utilizes the glutamate-rich protein (GLURP) as a carrier, and ProC6C includes a second domain (Pfs230-Pro) and a short 36-amino acid circumsporozoite protein (CSP) sequence. Healthy adults (n = 125) from a malaria-endemic area of Burkina Faso were immunized with 3 intramuscular injections, 4 weeks apart, of 30 [micro]g or 100 [micro]g R0.6C or ProC6C each adsorbed to Alhydrogel (AlOH) adjuvant alone or in combination with Matrix-M (15 [micro]g or 50 [micro]g, respectively). The allocation was random and double-blind for this phase I trial. RESULTS. The vaccines were safe and well tolerated with no vaccine-related serious adverse events. A total of 7 adverse events, mild to moderate in intensity and considered possibly related to the study vaccines, were recorded. Vaccine-specific antibodies were highest in volunteers immunized with 100 [micro]g ProC6C-AlOH with Matrix-M, and 13 of 20 (65%) individuals in the group showed greater than 80% transmission-reducing activity (TRA) when evaluated in the standard membrane feeding assay at 15 mg/mL IgG. In contrast, R0.6C induced sporadic TRA. CONCLUSION. All formulations were safe and well tolerated in a malaria-endemic area of Africa in healthy adults. The ProC6C-AlOH/ Matrix-M vaccine elicited the highest levels of functional antibodies, meriting further investigation. TRIAL REGISTRATION. Pan-African Clinical Trials Registry (https://pactr.samrc.ac.za) PACTR202201848463189. FUNDING. The study was funded by the European and Developing Countries Clinical Trials Partnership (grant RIA2018SV-2311).

Published
2024
Full Text
View/download PDF

2. A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults

Author

Tiono, Alfred B, Plieskatt, Jordan L, Ouedraogo, Alphonse, Soulama, Ben Idriss, Miura, Kazutoyo, Bougouma, Edith C, Naghizadeh, Mohammad, Barry, Aissata, Yaro, Jean Baptist B, Ezinmegnon, Sem, Henry, Noelie, Ofori, Ebenezer Addo, Adu, Bright, Singh, Susheel K, Konkobo, Augustin, Lövgren Bengtsson, Karin, Diarra, Amidou, Carnrot, Cecilia, Reimer, Jenny M, Ouedraogo, Amidou, Tienta, Moussa, Long, Carole A, Ouedraogo, Issa N, Sagara, Issaka, Sirima, Sodiomon B, Theisen, Michael, Tiono, Alfred B, Plieskatt, Jordan L, Ouedraogo, Alphonse, Soulama, Ben Idriss, Miura, Kazutoyo, Bougouma, Edith C, Naghizadeh, Mohammad, Barry, Aissata, Yaro, Jean Baptist B, Ezinmegnon, Sem, Henry, Noelie, Ofori, Ebenezer Addo, Adu, Bright, Singh, Susheel K, Konkobo, Augustin, Lövgren Bengtsson, Karin, Diarra, Amidou, Carnrot, Cecilia, Reimer, Jenny M, Ouedraogo, Amidou, Tienta, Moussa, Long, Carole A, Ouedraogo, Issa N, Sagara, Issaka, Sirima, Sodiomon B, and Theisen, Michael

Published
2024

3. A randomized first-in-human Phase 1 trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults

Author

Tiono, B. Alfred, primary, Plieskatt, Jordan L., additional, Ouedraogo, Alphonse, additional, Soulama, Ben Idriss, additional, Miura, Kazutoyo, additional, Bougouma, Edith C., additional, Naghizadeh, Mohammad, additional, Barry, Aissata, additional, Yaro, Jean Baptiste B., additional, Ezinmegnon, Sem, additional, Henry, Noelie B., additional, Ofori, Ebenezer, additional, Adu, Bright, additional, Singh, Susheel K., additional, Konkobo, Augustin, additional, Lövgren Bengtsson, Karin, additional, Diarra, Amidou, additional, Carnrot, Cecilia, additional, Reimer, Jenny M., additional, Ouedraogo, Amidou Z., additional, Tienta, Moussa, additional, Long, Carole A., additional, Nebie, Issa N., additional, Sagara, Issaka, additional, Sirima, Sodiomon B., additional, and Theisen, Michael, additional

Published
2024
Full Text
View/download PDF

6. N-Terminal Pfs230 Domain Produced in Baculovirus as a Biological Active Transmission-Blocking Vaccine Candidate

Author

Lee, Shwu-Maan, Wu, Chia-Kuei, Plieskatt, Jordan L., Miura, Kazutoyo, Hickey, John M., and King, C. Richter

Subjects
Vaccines, baculovirus, transmission-blocking vaccine, Pfs230, Plasmodium falciparum, malaria, Spotlight, recombinant protein
Abstract

Transmission-blocking vaccines have the potential to accelerate malaria parasite elimination by inducing antibodies that block parasite transmission from humans to mosquitoes. Pfs230, a gametocyte surface protein involved in gamete function, has long been a promising candidate. Due to the large size (3,135 amino acids), complex domains, and repeating 6-cysteine (6-Cys) motifs with a multitude of disulfide bonds, the feasibility of expression of a full-length protein has been difficult. A priority focus, therefore, has been on the generation of single domains, including N-terminal fragments. Here we utilized a heterologous expression system, baculovirus, to produce an N-terminal domain of Pfs230 (Pfs230C1). Pfs230C1 (amino acids 443 to 731) with a polyhistidine affinity tag was expressed in Super Sf9 cells. Since the native host lacks glycosylation machinery, a single N585Q mutation was made to eliminate potential N-linked glycosylation. The expressed protein, purified by nickel affinity, ion exchange, and size exclusion chromatography to >90% purity, was present in monomeric form with an observed mass of 33,510 Da (matching oxidized form). Peptide mapping and disulfide analysis confirmed the proper formation of predicted disulfide bonds. Antibodies, generated against Pfs230C1 in mice, bound to the gametocyte in an immunofluorescence assay (IFA) and demonstrated functional activity in both the standard membrane feeding assay (SMFA) and the exflagellation assay (EXA). The biochemical, biophysical, and immunological results reported herein support the continued advancement of an N-terminal Pfs230 antigen (Pfs230C1) as a component of a transmission-blocking vaccine. Our results also support the continued use of the scalable baculovirus expression system for the generation of complex Plasmodium proteins.

Published
2017

11. Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine

Author

Brelsford, Jill B., primary, Plieskatt, Jordan L., additional, Yakovleva, Anna, additional, Jariwala, Amar, additional, Keegan, Brian P., additional, Peng, Jin, additional, Xia, Pengjun, additional, Li, Guangzhao, additional, Campbell, Doreen, additional, Periago, Maria Victoria, additional, Correa-Oliveira, Rodrigo, additional, Bottazzi, Maria Elena, additional, Hotez, Peter J., additional, Diemert, David, additional, and Bethony, Jeffrey M., additional

Published
2017
Full Text
View/download PDF

14. The miRNAome of Opisthorchis viverriniinduced intrahepatic cholangiocarcinoma

Author

Peng, Jin, Feng, Yanjun, Rinaldi, Gabriel, Yonglitthipagon, Ponlapat, Easley, Samantha E., Laha, Therawach, Pairojkul, Chawalit, Bhudhisawasdi, Vajarabhongsa, Sripa, Banchob, Brindley, Paul J., Mulvenna, Jason P., Bethony, Jeffrey M., and Plieskatt, Jordan L.

Abstract

Intrahepatic cholangiocarcinoma (ICC) is an aggressive cancer, arising in the biliary ducts that extend into the liver. The highest incidence of ICC occurs in Southeast Asia, particularly in the Mekong River Basin countries of Thailand, Laos, Cambodia, and Vietnam, where it is strongly associated with chronic infection by the food-borne liver fluke Opisthorchis viverrini(OV), one of only three eukaryote pathogens considered Group one carcinogens. Intrahepatic cholangiocarcinoma is usually diagnosed at an advanced stage, with a poor prognosis and survival often less than 24months. Hence, biomarkers that enable the early detection of ICC would be desirable and have a potentially important impact on the public health in the resource-poor regions where this cancer is most prevalent. As microRNAs (miRNAs) remain well preserved after formalin fixation, there is much interest in developing them as biomarkers that can be investigated using tumor biopsy samples preserved in formalin fixed paraffin embedded (FFPE) tumor blocks. Recently, we reported the first comprehensive profiling of tissue-based miRNA expression using FFPE from the three most common subtypes of OV-induced ICC tumors: moderately differentiated ICC, papillary ICC, and well-differentiated ICC. We observed that each subtype of OV-induced ICC exhibited a distinct miRNA profile, which suggested the involvement of specific sets of miRNAs in the progression of this cancer. In addition, non-tumor tissue adjacent to ICC tumor tissue on the same FFPE block shared a similar miRNA dysregulation profile with the tumor tissue than with normal (non-tumor) liver tissue (individuals without ICC or OV infection). Herein, we provide a detailed description of the microarray analysis procedures used to derive these findings.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results